Company intelligence / Profile preview

Delft Imaging

's-Hertogenbosch, North Brabant, Netherlandsdelft.care ↗

Ownership: Private
Development stage: Other

Overview

Delft Imaging’s solutions have screened over six million people for tuberculosis across more than eighty-five countries. Their AI-driven platforms like CAD4TB are validated and widely adopted in low-resource settings to improve early disease detection and health equity. The company’s innovations have touched over twenty million lives through more than eighteen hundred installations worldwide.

Therapeutic areas: Women's HealthPulmonologyInfectious Diseases
Modalities: Device (Digital X-ray systems)Artificial intelligence software (Computer-aided detection)E-health software
Industry: Medical Imaging

Partnerships

Mercy Corps PakistanIOM [International Organization for Migration]KNCV Tuberculosis Foundation/Nigeria USAID projectvarious Ministries of Health in Africa and Asia.

Beyond the preview

Go deeper on Delft Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delft Imaging.

Explore the full profile